# InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA filing for AVERSA Fentanyl, the company’s flagship abuse-deterrent opioid patch. AVERSA Fentanyl is designed to deter misuse and accidental exposure, with potential peak annual U.S. sales estimated between $80 million and $200 million. The AVERSA(TM) technology is protected by patents in 46 countries, including the United States, Europe, and Japan.

 To view the full press release, visit https://ibn.fm/3r3N9

 About Nutriband Inc.

 We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

 The Company’s website is www.nutriband.com . Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-nutriband-inc-nasdaq-ntrb-founder-gareth-sheridan-returns-as-ceo-to-lead-final-development-phase-of-aversa-fentanyl/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-founder-returns-as-ceo-to-lead-fentanyl-patch-development/8ea73dc894765125a914b80dc4143407) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/27/apexqhl_.webp)